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Background:Antiphospholipid antibodies (aPLs) have been associated with thrombosis in
the antiphospholipid antibody syndrome (APS) and with atherosclerotic vascular events in
patients without APS. We examined the significance of aPLs in transient ischemic attack
(TIA). Patients/methods: Patients with TIA <48 h from symptom onset were prospec-
tively enrolled. Traditional aPLs, including anticardiolipin and β2-glycoprotein-I (β2GPI), and
newer aPLs, including anti-phosphatidylserine/prothrombin (aPS/PT), β2GPI Domain 4/5
and β2GPI Domain 1 were measured. Primary outcome was a composite of stroke or
death within 90 days or identification of a high risk stroke mechanism. Secondary out-
comes were stroke or death and the presence of clinical/sub-clinical atherosclerosis.
Results: Over 4.5 years, 167 patients were enrolled. Forty one patients (25%) had the
composite endpoint. Antibodies were measured in 158 subjects. aPS/PT IgG antibodies
were significantly associated with stroke/death (OR 16.3, 95% CI 2.3–116.7, p=0.005) and
were non-significantly associated with the composite endpoint (OR 4.7, 95% CI 0.8–29.2,
p=0.10). In multivariate analysis adjusting for ABCD2 risk score, aPS/PT IgG remained
associated with stroke/death (OR 15.7, 95% CI 2.0–125.6, p=0.009). Other aPLs were
not associated with clinical outcome and no association between APLs and atheroscle-
rosis was identified. Conclusion: In contrast to other aPLs, aPS/PT IgG antibodies are
independently associated with stroke or death in patients with TIA.
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INTRODUCTION
Antiphospholipid antibodies (aPLs) are a diverse collection of
autoantibodies which are directed at plasma proteins bound to
phospholipid membranes. Traditional aPLs include anticardi-
olipin (aCL) and β-2-glycoprotein-I (β2GPI) antibodies. These
antibodies have been associated with thrombosis in the antiphos-
pholipid antibody syndrome (APS), which is characterized by arte-
rial and venous thrombosis as well as recurrent fetal loss (Cohen
et al., 2010). Newly defined sub-classes of aPLs, including antibod-
ies toβ2GPI Domain 1 (β2GPI D1) andβ2GPI Domain 4/5 (β2GPI
D4/5) and anti-phosphatidylserine/prothrombin (aPS/PT), have
been associated with thrombosis; although there is not yet suf-
ficient evidence to include these antibodies into APS diagnos-
tic criteria (Atsumi et al., 2000; Bertolaccini et al., 2005, 2011;
Forastiero et al., 2005; Bizzaro et al., 2007; Sanmarco et al.,
2007). Recently, aPLs have also been linked to atherosclerotic
vascular disease in subjects without APS (Farsi et al., 1999;
Brey et al., 2001; Staub et al., 2003; Veres et al., 2004; Iver-
son et al., 2006; Franck et al., 2007; Bizzaro et al., 2010).
These findings raise the question of whether APL antibod-
ies may be useful as biomarkers of vascular risk in patients
without APS.
Patients with transient ischemic attack (TIA) have a high
short-term risk of stroke, with estimates up to 15% at 90 days
(Kleindorfer et al., 2005; Easton et al., 2009). Reliable identifica-
tion of TIA patients at highest risk could be used to select patients
for aggressive monitoring and therapeutic interventions. Clinical
risk scores, such as the ABCD2 score, incorporate features of the
patient’s history and symptoms to estimate subsequent stroke risk
(Johnston et al., 2007). This risk score has a number of important
limitations (Cucchiara et al., 2006; Perry et al., 2011). Risk predic-
tion may be enhanced by incorporating results of brain imaging
with MRI to assess for infarction and/or vascular imaging to assess
for atherosclerotic carotid stenosis, both of which are associated
with a higher risk independent of the ABCD2 score (Merwick et al.,
2010; Giles et al., 2011). Unfortunately, these studies are resource
intensive and not always available in the emergency setting. There
is a great need to identify other biomarkers which can reliably
identify TIA patients who are at high risk of subsequent stroke.
Because aPLs are potentially associated with thrombosis and
atherosclerosis, they may function as biomarkers of risk after TIA.
The purpose of this study was to examine the association of both
traditional and newer aPLs with outcome after TIA, in subjects
without a clinical diagnosis of APS.
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MATERIALS AND METHODS
STUDY DESIGN
This study was a retrospective analysis of a prospectively collected
cohort of patients with TIA. Subjects were enrolled within 48 h
of symptom onset. To be included subjects must have had focal
neurologic deficits presumed to be due to a vascular cause. Tran-
sient neurologic symptoms which were deemed to be non-vascular
by the treating neurologist were excluded. The traditional time-
based definition of TIA was used (symptom resolution within
24 h). Subjects were excluded if they had a terminal illness which
was likely to limit their evaluation or prevent full study follow-
up or if they were on warfarin with an INR ≥1.5 at the time of
enrollment. Patients on warfarin were excluded by design because
of the impact of long-term anticoagulation on D-dimer, a bio-
marker which was previously assessed in this cohort (Cucchiara
et al., 2009). For each subject, a standardized case report form
was completed which captured clinical information and results
of diagnostic testing. Final determination of TIA mechanism and
clinical events was made at 90-day follow-up. ABCD2 clinical risk
scores were calculated and categorized as low (0–3), medium (4–
5), or high (6–7) as previously described (Johnston et al., 2007).
Collection of all clinical and outcome data was blinded to results
of biomarker testing. A detailed description of study methods has
been previously published (Cucchiara et al., 2006). Informed con-
sent was obtained from all subjects and the study protocol was
approved by the local institutional review board.
The primary outcome measure was a composite endpoint of
stroke or death within 90 days, ≥50% stenosis in a vessel refer-
able to the presenting TIA, or cardioembolic source requiring
anticoagulation. The endpoint was pre-specified before patient
enrollment or analysis. It was designed to identify high risk TIA
patients requiring emergent evaluation and specific early inter-
ventions. In observational studies, clinical interventions may pre-
vent high risk patients from having an event. Outcomes which
focus solely on clinical events may not capture these high risk
patients. The combined outcome used in this study ensures that
these patients are appropriately categorized. Two secondary out-
come measures were: (1) stroke or death at 90 days alone, and
(2) the presence of atherosclerotic disease. Atherosclerotic disease
was defined to include both clinical atherosclerosis (history of
coronary artery disease/myocardial infarction, stroke, peripheral
vascular disease, carotid endarterectomy, or symptomatic large-
artery stenosis) and sub-clinical atherosclerosis defined by the
presence of atherosclerotic plaque on imaging.
BLOOD SAMPLING AND ANTIBODY TESTING
For all subjects peripheral venous blood was collected into ster-
ile tubes containing 3.2% sodium citrate and then centrifuged at
1,300g for 10 min. Plasma was extracted and centrifuged at 10,000g
for 3 min. Samples were frozen at−80˚C until the time of analysis.
Specimens were tested for aPL antibodies at a dilution of 1:101
using the following ELISA assays: QUANTA Lite® anti-β2GPI IgG,
IgA, IgM, anti-β2GPI-domain 4/5 IgA, anti-β2GPI-domain 1 IgG,
QUANTA Lite® anticardiolipin (ACA) IgG, IgA, IgM, QUANTA
Lite® anti-PS/PT IgG, IgM, IgG/IgM. All ELISA assays were manu-
factured by INOVA Diagnostics, San Diego, CA, USA and are FDA-
cleared for in vitro use with the exception of the β2GPI-domain
1 IgG, β2GPI-domain 4/5 IgA, and the PS/PT IgG/IgM kits which
are research only. All tests were performed according to the man-
ufacturer’s instructions. Results for aCL and β2GPI were derived
from five point standard curves calibrated against accepted refer-
ence standards. For all antibodies, the manufacturer’s suggested
thresholds were used to define a positive test. These thresholds are
determined after testing clinical samples, normal controls, disease
controls, and potentially cross-reactive samples.
STATISTICAL ANALYSIS
Summary statistics were computed using means, medians, and
counts. Groups of patients were compared with t -tests, Wilcoxon
ranked sum, χ2, and Fisher’s exact test as appropriate. The pri-
mary analysis dichotomized aPL testing as positive or negative
on the basis of pre-defined thresholds. We tested for an associ-
ation between aPL antibodies and the composite outcome using
Fisher’s exact test and univariate logistic regression. Similar analy-
ses were conducted to evaluate the relationships between aPLs and
the secondary outcomes. Antibodies which were associated with
outcomes with p≤ 0.10 were included in a multivariable model
with ABCD2 score. ABCD2 score was treated as a categorical vari-
able, with scores grouped into low, medium, and high risk (0–3,
4–5, and 6–7, respectively). All statistical analyses were performed
using STATA version 11.0 (Stata corporation, College Station, TX,
USA).
RESULTS
From November 2002 to June 2007, 167 subjects were enrolled. Of
these, 164 subjects were available for 90 day follow-up. Of the three
subjects who were not available for 90 day follow-up, one had a
carotid occlusion at presentation and was categorized as endpoint
positive. The other two subjects had no events or high risk mech-
anisms identified at hospital discharge and were categorized as
endpoint negative. For nine subjects aPLs could not be measured
due to missing or insufficient blood sample volume, leaving a final
sample size of 158. Baseline characteristics of enrolled subjects are
summarized in Table 1.
Overall there were 40 subjects (25%) with the composite end-
point. There were 25 subjects (15%) with>50% stenosis, 13 (8%)
with cardioembolism, and 8 (5%) with clinical events. Of the clin-
ical events five were strokes and three were deaths. There were
five subjects who had both a clinical event and a high risk TIA
mechanism. No subjects were clinically diagnosed with APS.
Using pre-defined thresholds to define positivity (Table 2), 16
of 158 subjects (10%) were positive for traditional aPLs (aCL or
β2GPI IgG/M). There were 19 (12%) positive for aPS/PT IgM or
IgG, and 26 (16%) for β2GP1 D4/5 IgA. No subjects were pos-
itive for B2GPI D1 IgG. In the univariate analysis there was no
association between traditional aPLs (aCL IgA/G/M and β2GPI
IgA/G/M), newer β2GPI sub-classes (D 4/5 IgA and D1 IgG),
or aPS/PT IgM with either the composite endpoint or the clin-
ical endpoint of stroke or death. Elevated aPS/PT IgG antibodies
were modestly associated with the composite endpoint, although
this association did not reach statistical significance (OR 4.7,
95% CI 0.8–29.2, p= 0.10). There was a significant association
between aPS/PT IgG antibodies and the secondary endpoint of
stroke or death (OR 16.3, 95% CI 2.3–116.7, p= 0.005). These
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results are summarized in Table 2. In a multivariable model
(Table 3) which included ABCD2 score, aPS/PT IgG remained
associated with stroke or death (OR 15.7, 95% CI 2.0–125.6,
p= 0.009).
Clinical or sub-clinical atherosclerosis was present in 100
subjects (60%). APLs were not associated with atherosclerosis
(Table 2).
Table 1 | Baseline characteristics.
n (%)
Age (mean±SD) 62±15
Male sex 72 (46%)
Time from onset to enrollment, hours (mean±SD) 26.4±12.7
Duration of symptoms
<10 min 23 (15%)
10–59 min 42 (26%)
≥60 min 93 (59%)
Blood Pressure at Presentation
Systolic (mean±SD) 153±27
Diastolic (mean±SD) 83±15
History of:
Hypertension 103 (65%)
Diabetes 34 (22%)
CAD/MI 20 (13%)
Hyperlipidemia 63 (40%)
Prior stroke 28 (18%)
PAD 8 (5%)
Current smoker 26 (16%)
Migraine 16 (10%)
ABCD2 Score
0–3 58 (37%)
4–5 79 (50%)
6–7 21 (13%)
DISCUSSION
Patients with TIA have a high short-term risk of stroke. Bio-
markers to identify patients at high risk of subsequent stroke
would assist the selection of patients for aggressive monitor-
ing and therapeutic interventions. In the cohort of subjects
with TIA examined in this study, IgG antibodies against the
phosphatidylserine-prothrombin complex were associated with
clinical outcome (stroke or death). The association with outcome
persisted after adjustment for the ABCD2 score, which is the most
widely used clinical risk score for predicting outcome after TIA.
In contrast, traditional aPLs (aCL and β2GPI) and newer aPLs
directed against the D1 and D4/5 subunits of β2GPI were not asso-
ciated with outcome after TIA and no antibodies were associated
with atherosclerosis.
Transient ischemic attack may be caused by a wide range of
disease processes, including cardioembolism, large-artery ather-
osclerosis, non-atherosclerotic vasculopathy such as dissection,
small artery lipohyalinosis, and hypercoagulable states. The patho-
physiologic link between outcome after TIA and aPS/PT IgG is
uncertain, but may be mediated by thrombosis, which is a common
Table 3 | Multivariable models, aPS/PT IgG positivity >30 units.
OR (95% CI) p-Value
COMPOSITE OUTCOME
aPS/PT IgG 4.3 (0.7–27.8) 0.12
ABCD2 0.07
0–3 Ref – –
4–5 1.7 (0.7–4.0) 0.23
6–7 3.5 (1.2–10.6) 0.02
STROKE OR DEATH
aPS/PT IgG 15.7 (2.0–125.6) 0.009
ABCD2 0.15
0–3 Ref – –
4–5 2.7 (0.3–26.1) 0.39
6–7 9.1 (0.8–99.5) 0.07
Table 2 | Univariate analysis.
Positive
cut-point
# Positive
(n=158)
% Positive
w/athero*
p-Value Composite outcome
OR (95% CI)
p-Value Stroke or death
OR (95% CI)
p-Value
aPS/PT IgG ≥30 units 5 (3%) 100 0.16 4.7 (0.8–29.2) 0.10 16.3 (2.3–116.7) 0.005
aPS/PT IgM ≥30 units 15 (9%) 67 0.79 1.1 (0.3–3.6) 0.90 3.5 (0.6–19.2) 0.15
aCL IgG ≥20 units 3 (2%) 100 0.29 6.2 (0.5–69.8) 0.14 – –
aCL IgM ≥20 units 5 (3%) 60 1.00 0.73 (0.1–6.7) 0.78 – –
aCL IgA ≥20 units 0 (0%) – – – – – –
β2GPI IgG ≥20 units 2 (1%) 100 0.53 – – – –
β2GPI IgM ≥20 units 9 (6%) 67 1.00 1.5 (0.4–6.4) 0.57 2.5 (0.3–23.2) 0.41
β2GPI IgA ≥20 units 19 (12%) 68 0.47 1.1 (0.4–3.3) 0.85 1.1 (0.1–9.6) 0.92
D4/5 IgA ≥25 units 26 (16%) 58 0.66 0.9 (0.3–2.3) 0.77 0.7 (0.1–6.1) 0.76
D1 IgG ≥25 units 0 (0%) – – – – – –
Legend: anti-phosphatidylserine-prothrombin (aPS/PT), β-2-glycoprotein-I (β2GPI), anticardiolipin antibodies (aCL).
*Percentage of subjects who were antibody positive with clinical or sub-clinical atherosclerosis.
Blank spaces indicate no subjects who were antibody positive had the outcome of interest.
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pathologic process underlying many TIAs. The mechanism of aPL-
induced thrombosis is thought to involve antibody binding to
platelets and endothelial cells with subsequent activation of the
clotting cascade (Horstman et al., 2009; Cohen et al., 2010). Dis-
ruption of annexin A5 anticoagulant activity has been implicated
in this process, and activation of complement may also play a role
(Rand, 2000; Avalos and Tsokos, 2009). aPS/PT antibodies have
previously been associated with thrombosis (Bertolaccini et al.,
2005). They correlate with clinical symptoms of APS and have
been previously reported in subjects with acute ischemic stroke
(Atsumi et al., 2000; Okuma et al., 2006). An international task-
force recently recommended a multi-center study evaluating the
utility of aPS/PT as an additional marker for APS (Bertolaccini
et al., 2011).
The relationship between aPLs and atherosclerosis is less well
established. β2GPI is a component of atherosclerotic plaque
(George et al., 1999). It has been hypothesized that autoantibodies
toβ2GPI contribute to the uptake of oxidized LDL by macrophages
leading to the development of foam cells and plaque (Matsuura
et al., 2002, 2003; Staub et al., 2006). APLs, particularly β2GPI and
its D4/5 and D1 subunits,have been associated with clinical athero-
sclerotic disease (Iverson et al., 2006; Franck et al., 2007). Although
atherosclerosis was common in antibody positive patients in the
present study, we did not observe an association between any of
the measured antibodies and atherosclerosis.
Some subsets of aPLs were relatively common in this cohort of
TIA patients. For instance, IgA antibodies against β2GPI and the
D4/5 subunit were present in a large percentage of subjects (12
and 16%, respectively). In contrast, aCL antibodies were relatively
uncommon, with IgG in 2%, IgM in 3%, and IgA in 0%. This is sig-
nificantly lower than the percentage of positive subjects reported in
the APASS study (Anti-Phospholpid Antibodies and Subsequent
thrombo-occlusive events in patients with ischemic Stroke; Levine
et al., 2004). Of the 1770 subjects in APASS, 19% had aCL IgG
antibodies, 5% had aCL IgM antibodies, and 10% aCL IgA anti-
bodies. APASS did not measure β2GPI or other aPLs (Levine et al.,
2004). Differences in the observed prevalence of aCL may be due
to differences in the study populations. APASS was nested within
a clinical trial and all participants had an ischemic stroke, rather
than a TIA. APASS also used a different aCL assay (Corgenix Inc.,
Denver, CO, USA). Differences in specificities of the assays maybe
partially responsible for the observed results. There is well doc-
umented variability across aPL assays. Inter-assay agreement is
lower with aCL compared to β2GPI and lower with low-positive
antibody titers, which comprised many of the positive samples in
APASS (Audrain et al., 2004).
This study has several important limitations. As mentioned
above, inter-assay agreement for aPLs is low. In the present study,
all assays were performed with kits from the same manufacturer
(INOVA Diagnostics). Our results may not be directly extrapo-
lated to assays from other suppliers. The relatively small sample
size limits power to detect associations. Although detailed clini-
cal information is available for all subjects, the small number of
clinical events limits our ability to determine whether the mea-
sured association between aPS/PT IgG and outcome is mediated
by thrombosis, atherosclerosis, or some other mechanism. Fur-
thermore, the findings should be interpreted with caution due to
the small number of clinical events. There were only two patients
who had both an elevated aPS/PT IgG and a clinical event. Thresh-
olds to define positive tests were defined by the manufacturer and
not specific to TIA patients. Serum was only collected at the time of
the TIA. Subjects were not followed to determine if aPLs remained
positive. Furthermore, a functional test of phospholipid depen-
dent clotting was not performed as a part of the research study;
although, clinically none of the subjects were suspected or diag-
nosed with APS. Since antibody measurements occurred after the
vascular event, the possibility that aPL positivity is an epiphenom-
enon related to vascular occlusion or tissue injury should also be
considered.
In conclusion, we found that aPS/PT IgG antibodies were asso-
ciated with clinical outcome after TIA in a population of patients
without APS. This association was not found with the other
aPL antibodies tested. This suggests that aPS/PT IgG antibodies
may be useful for risk stratifying patients after TIA; although,
larger, prospective studies are needed to extend and validate these
findings.
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